Oryzon Genomics


Market Cap€167.4m

Last Close €3.16

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and SCLC; its CNS product vafidemstat is in Phase IIb trials in BPD, schizophrenia and also being investigated for precision medicine. ORY-3001 is being developed for certain orphan indications.

More Oryzon Genomics content >

Investment summary

Oryzon develops small molecule inhibitors for epigenetic targets. It has completed five Phase II and has three ongoing Phase II trials with two assets: iadademstat and vafidemstat. Oryzon reported data in March 2021 from its two Phase IIa trials focusing on AD (ETHERAL and REIMAGINE-AD) that confirm vafidemstat is safe and effective in controlling aggression/agitation, a key focus area. In July 2020, results from the Phase IIa REIMAGINE trial with vafidemstat for aggressiveness in psychiatric diseases showed improvement in all cohorts (BPD, ADHD and ASD). Oryzon is conducting the Phase IIb trial for vafidemstat in BPD (PORTICO) and a Phase IIb trial for schizophrenia (EVOLUTION) which received approval from Spanish regulators in July. Oryzon is also developing a precision medicine approach for vafidemstat in genetically defined patients with certain CNS disorders. In June 2021, Oryzon presented an update from the Phase II ALICE trial (iadademstat plus azacitidine) in AML, which continues to show a large response benefit.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2019A 10.3 (3.7) (4.6) (8.81) N/A N/A
2020A 9.5 (4.1) (4.8) (6.88) N/A N/A
2021E 9.9 (4.1) (4.2) (5.51) N/A N/A
2022E 9.9 (4.1) (4.2) (5.12) N/A N/A
Industry outlook

Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and potentially a favourable safety/efficacy profile than the first generation HDAC inhibitors.

Last updated on 18/01/2022
Content on Oryzon Genomics
Oryzon Genomics – Edison Open House interview
Healthcare | Edison TV | 3 February 2021
View more
Register to receive research on Oryzon Genomics as it is published
Share price graph
Balance sheet
Forecast net cash (€m) 13
Forecast gearing ratio (%) N/A
Price performance
Actual 14.5 0.2 (20.3)
Relative* 8.4 1.9 (25.1)
52-week high/low €4.2/€2.7
*% relative to local index
Key management
Carlos Buesa CEO